PharmAla Files Patent for Novel MDXX Molecule PharmAla-1
July 31, 2023 08:30 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, July 31, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney
July 20, 2023 09:07 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, July 20, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
PaxMedica Grants Exclusive Pharmacy Distribution Rights for PAX-101 to Vox Nova, LLC
July 06, 2023 08:00 ET
|
PaxMedica, Inc.
· Agreement for PAX-101 (suramin IV) Distribution in the U.S. for up to 7 years · VoxNova will be responsible for physician registration, safety monitoring and reimbursement for treatment, as...
Autism Spectrum Disorder Treatment Market Size to Surpass USD 3.42 billion by 2030, exhibiting a CAGR of 7.9%
June 21, 2023 04:50 ET
|
Fortune Business Insights
Pune, India, June 21, 2023 (GLOBE NEWSWIRE) -- According to Fortune Business Insights, global Autism Spectrum Disorder Treatment Market size was valued at USD 1.93 billion in 2022 and is projected...
CAI Neurodiverse Solutions and Drexel University Create Job Opportunities for Philadelphia-area Neurodivergent Graduates
May 17, 2023 09:00 ET
|
CAI
ALLENTOWN, Pa., May 17, 2023 (GLOBE NEWSWIRE) -- CAI, a global technology services firm, and Drexel University’s Center for Autism and Neurodiversity (CAN), a student-centered program that provides...
Little Leaves Behavioral Services Appoints Dr. Ivy Chong Chief Clinical Officer
May 16, 2023 08:40 ET
|
Little Leaves
SILVER SPRING, Md., May 16, 2023 (GLOBE NEWSWIRE) -- Little Leaves Behavioral Services, a leading provider of center-based behavioral health services and early intervention for preschool-aged...
Axial Therapeutics Announces Age Expansion in Global Phase 2b Clinical Trial for Irritability Associated with Autism Spectrum Disorder (ASD)
April 04, 2023 08:00 ET
|
Axial Therapeutics
-- Children aged 5 to 17 with autism are now eligible to enroll in the clinical trial of AB-2004, a gut targeted, molecular therapeutic -- -- Novel small molecule microbiome approach focused on...
Axial Therapeutics Announces Key Research and Development Promotions to Advance Clinical and Preclinical Pipeline of Small Molecule Microbiome Therapeutics
March 29, 2023 08:00 ET
|
Axial Therapeutics
– Phase 2b clinical trial for AB-2004 in autism irritability ongoing and enrollment anticipated to be complete by end of 2023 – – IND-enabling studies ongoing for Parkinson’s Disease development...
STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD
March 27, 2023 07:25 ET
|
STALICLA
STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD The combination of STALICLA and...
Little Leaves Behavioral Services Announces the Opening of Its Newest Location in Frederick, Maryland
March 13, 2023 08:38 ET
|
Little Leaves
FREDERICK, Md., March 13, 2023 (GLOBE NEWSWIRE) -- Little Leaves Behavioral Services, a leading provider of center-based behavioral health services for preschool-aged children on the autism...